Patients with psoriasis who had low body surface area (BSA) involvement experienced similarly poor QOL and symptom burden compared to patients with higher BSA.

Certain pain-related pruritus descriptors may independently predict mental health outcomes, sleep disturbance, and QOL reduction in patients with AD.

Key Takeaways A standardized definition of on-treatment remission in plaque psoriasis is crucial for aligning treatment goals and improving patient care. Remission is defined as maintaining 0% BSA ...

Experts defined on-treatment remission for plaque psoriasis as maintaining a BSA of 0% or IGA of 0 for at least 6 months. The standardized benchmarks can be applied in research and practice settings.

Among 1640 patients who initiated biologic therapy, 7.0% had low BSA involvement, 46.9% had medium BSA, and 46.2% had high BSA. Despite these differences in skin involvement, PROs showed ...

Specific sites of involvement also can help with estimating BSA. For example, involvement of a hand is about 1% BSA, psoriasis on both knees about 2%, and the chest about 5-6%, said Asempa.

BSA Motorcycles are on the verge of a comeback, reviving the heritage of the brand’s 1960s heyday — by 1969, the conglomerate of BSA and Triumph made up 80 percent of Britain’s overseas ...

Results Among 627 patients with PsA, three clusters were identified: mild PsA and psoriasis only (PsO) (Cluster 1, 47.4%), severe PsA and mild PsO (Cluster 2, 34.3%) and severe PsA and severe PsO ...

If the cause of your Auspitz sign is psoriasis, for example, it’s important to know that psoriasis is a chronic condition that can come and go. Sometimes, psoriasis can calm down and clear up ...

By 1969, BSA is said to have accounted for more than 80% of the motorcycles exported from Britain. As impressive as BSA's legacy is, it's still possible you don't know what the company's three ...

People may refer to plaque psoriasis as psoriasis vulgaris or simply psoriasis. The FDA approved Otezla in 2014. It belongs to a class of medicines called phosphodiesterase-4 (PDE-4) inhibitors.